Prognostic value of circulating tumor cells combined with neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma

Table 1 Clinical characteristics of the hepatocellular carcinoma patients in the study

Variable	n	%
Patients	124	100.0
Sex
Male	112	90.3
Female	12	9.7
Age (years)
< 60	73	58.9
≥ 60	51	41.1
HBV
Negative	54	43.5
Positive	70	56.5
Smoke
Negative	62	50.0
Positive	62	50.0
Alcohol
Negative	71	57.3
Positive	53	42.7
Hypertension
Negative	94	75.8
Positive	30	24.2
Diabetes mellitus
Negative	107	86.3
Positive	17	13.7
Liver cirrhosis
Negative	78	62.9
Positive	46	37.1
Child-Pugh class
A	65	52.4
B	59	47.6
BCLC stage
B	9	7.3
C	115	92.7
ALBI grade
1	64	51.6
2	55	44.4
3	5	4.0
Serum AFP, ng/mL
< 400	75	60.5
≥ 400	49	39.5
Number of tumors
< 2	38	30.6
≥ 2	86	69.4
Tumor diameter, cm
< 5	49	39.5
≥ 5	75	60.5
PVTT
Negative	69	55.6
Positive	55	44.4
Lymph node metastasis
Negative	43	34.7
Positive	81	65.3
Extrahepatic metastases
Negative	85	68.5
Positive	39	31.5

HBV: Hepatitis B virus; BCLC: Barcelona clinic liver cancer; ALBI: Albumin-bilirubin; AFP: Alpha-fetoprotein; PVTT: Portal vein tumor thrombus; NLR: Neutrophil-lymphocyte ratio; CTC: Circulating tumor cell.